Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives $42.75 Average Price Target from Brokerages

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $42.75.

KLRA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 target price for the company. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price target for the company. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target for the company.

Kailera Therapeutics Stock Down 3.3%

KLRA stock opened at $18.89 on Friday. Kailera Therapeutics has a twelve month low of $18.69 and a twelve month high of $28.23.

Insider Activity

In other news, major shareholder Rtw Investments, Lp purchased 500,000 shares of Kailera Therapeutics stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. Following the transaction, the insider directly owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. This trade represents a 4.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Adam Koppel purchased 1,562,500 shares of Kailera Therapeutics stock in a transaction dated Monday, April 20th. The shares were purchased at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director directly owned 22,583,268 shares in the company, valued at approximately $361,332,288. This represents a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 10,460,938 shares of company stock worth $167,375,008 in the last three months.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.